The analyst rating for CSPC PHARMA was maintained at "Buy" by Nomura due to several positive factors. The firm expects a 20% year-over-year revenue growth in 4Q25, slightly surpassing market consensus. Additionally, the anticipated increase in collaboration revenue and a higher gross profit margin contributed to the positive outlook. Nomura also raised its revenue and earnings forecasts for FY2025 and FY2026, which further supported the decision to elevate the target price from $9.11 to $12.04.

CICC

Outperform

maintain

$11 -> $12

2026-02-02

Reason

CICC

Price Target

$11 -> $12

2026-02-02

maintain

Outperform

Reason

The analyst rating for CSPC Pharma (01093.HK) is maintained at "Underperform" by BofAS due to sales pressure, despite the positive developments in their collaboration with AstraZeneca and the potential for milestone revenue recognition from their R&D pipeline. CICC, on the other hand, raised its target price to $12 and kept its rating at "Outperform," reflecting confidence in the company's earnings forecasts and innovative assets.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for 01093

Unlock Now

01093 Should I Buy

01093 Should I Buy

Should You Buy CSPC PHARMA (01093) Today? Analysis, Price Targets, and 2026 Outlook.

No data

No data

Growth

Profitability

Efficiency

People Also Watch